J&J expanding vaccine trial to adolescents

Hospital News

Johnson & Johnson will soon start testing its COVID-19 vaccine candidate in U.S. adolescents, the company announced Friday. The company plans to begin testing the vaccine in a small number of 16 and 17 year olds as part of an ongoing Phase 2 trial for adults, gradually expanding the trial to children aged 12-17 after reviewing the initial data.

It is currently enrolling adolescents in Spain and the United Kingdom and expects to start enrolling them soon in the U.S., Netherlands and Canada, followed by Brazil and Argentina.

In February, the U.S. Food and Drug Administration authorized emergency use of the vaccine for individuals 18 and older. 

Products You May Like

Articles You May Like

Urgent care centers draw some ER visits but associated with higher spending overall
The ACA Family Glitch and Affordability of Employer Coverage
CDC director declares racism ‘serious public health threat’
CMS selects applicants for opioid use disorder treatment model
CMS proposes payment increase for hospices in FY 2022